Last reviewed · How we verify

Actelion — Portfolio Competitive Intelligence Brief

Actelion pipeline: 3 marketed, 0 filed, 9 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 9 Phase 3 1 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Flolan® Flolan® marketed
JNJ-67896049 JNJ-67896049 marketed
Tracleer® Tracleer® marketed Endothelin receptor antagonist Endothelin receptor A (ETA) and Endothelin receptor B (ETB) Cardiovascular
macitentan (ACT-064992) macitentan (ACT-064992) phase 3 Endothelin receptor antagonist ETA and ETB receptors Cardiovascular
EFI/ACT-385781A EFI/ACT-385781A phase 3 Selective endothelin receptor antagonist Endothelin receptor (ETA/ETB) Cardiovascular
Macitentan/Tadalafil FDC Macitentan/Tadalafil FDC phase 3 Endothelin receptor antagonist / Phosphodiesterase-5 inhibitor combination Endothelin receptor A and B / Phosphodiesterase-5 Cardiovascular
iloprost (5 µg) iloprost (5 µg) phase 3 prostacyclin analogue prostacyclin receptor Cardiovascular
i.v. selexipag i.v. selexipag phase 3 prostacyclin receptor agonist IP receptor Cardiovascular
selexipag (Uptravi) selexipag (Uptravi) phase 3 prostacyclin receptor agonist IP receptor Cardiovascular
SOC: Soluble guanylate cyclase stimulator SOC: Soluble guanylate cyclase stimulator phase 3 Soluble guanylate cyclase stimulator Soluble guanylate cyclase (sGC) Cardiovascular
FDC macitentan/tadalafil FDC macitentan/tadalafil phase 3 Endothelin receptor antagonist / Phosphodiesterase-5 inhibitor combination Endothelin receptor A and B / Phosphodiesterase-5 Cardiovascular
ACT-293987 ACT-293987 phase 3 Soluble guanylate cyclase (sGC) stimulator Soluble guanylate cyclase (sGC) Pulmonary Hypertension / Fibrosis

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie (prior sponsor, Abbott) · 1 shared drug class
  2. Bayer · 1 shared drug class
  3. Chinese University of Hong Kong · 1 shared drug class
  4. Dr Sudarshan Rajagopal · 1 shared drug class
  5. Eli Lilly and Company · 1 shared drug class
  6. Elpen Pharmaceutical Co. Inc. · 1 shared drug class
  7. National Heart, Lung, and Blood Institute (NHLBI) · 1 shared drug class
  8. University of Arizona · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Actelion:

Cite this brief

Drug Landscape (2026). Actelion — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/actelion. Accessed 2026-05-13.

Related